Drugs.com - Clinical Trials

Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301

KANSAS CITY, Kan., March 04, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline...

Mar 5, 2025 - 04:49
 0
Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301
KANSAS CITY, Kan., March 04, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline...
Read More

Tags:

Previous Article

Kerten Hospitality opens Cloud 7 hotel in Rome

Next Article

The Lana Dubai partners with Pomellato for exclusive Majlis pop-up

Related Posts

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Pyxis Oncology Granted FDA Fast Track Designation for P...

Feb 27, 2025  0

Lundbeck’s Potential Treatment Amlenetug for Multiple System Atrophy Receives Fast Track Designation From the FDA

Lundbeck’s Potential Treatment Amlenetug for Multiple S...

Feb 17, 2025  0

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

Lipella Pharmaceuticals Granted FDA Approval for Expand...

Feb 9, 2025  0